论文部分内容阅读
目的探讨贝伐单抗(bevacizumab,BEV)联合OHLF3方案治疗晚期胃癌的临床疗效及不良反应。方法 34例经病理确诊的晚期胃癌患者应用贝伐单抗5mg/kg,第1天,每3周1次;联合OHLF3方案化疗。结果 34例患者中总反应率为58.8%(20/34);完全缓解率为20.6%(7/34);主要不良反应为血液和神经毒性。生活质量改善率为82.6%。结论贝伐单抗联合OHLF3方案治疗晚期胃癌疗效较好,不良反应能耐受,生活质量有显著改善。
Objective To investigate the clinical efficacy and adverse reactions of bevacizumab (BEV) combined with OHLF3 regimen in the treatment of advanced gastric cancer. Methods Thirty-four cases of pathologically confirmed advanced gastric cancer patients were treated with bevacizumab 5 mg/kg on the first day and every 3 weeks; combined with OHLF3 chemotherapy. Results The overall response rate was 58.8% (20/34) in 34 patients; the complete remission rate was 20.6% (7/34); the main adverse reactions were blood and neurotoxicity. The quality of life improvement rate was 82.6%. Conclusion Bevacizumab combined with OHLF3 regimen is effective for the treatment of advanced gastric cancer, adverse reactions can be tolerated, and quality of life is significantly improved.